Page 7 - Lisa Raffensperger News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Talaris Therapeutics Announces Pricing of Initial Public Offering BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share. All shares are being offered by Talaris. The gross proceeds to Talaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $150.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “TALS” on May 7, 2021. The offering is expected to close on May 11, 2021, subject to the satisfaction of customary closi

New yorkUnited statesLisa raffenspergerMorgan stanleyEquity syndicate departmentExchange commission onTalaris therapeutics incGuggenheim securitiesProspectus departmentSyndicate departmentEvercore groupMorgan stanley coTalaris therapeuticsNasdaq global select marketExchange commissionOne federal street